<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03539094</url>
  </required_header>
  <id_info>
    <org_study_id>201707010</org_study_id>
    <nct_id>NCT03539094</nct_id>
  </id_info>
  <brief_title>Intermittent Fasting in Multiple Sclerosis</brief_title>
  <acronym>IFMS</acronym>
  <official_title>Randomized Controlled Trial on Intermittent Fasting in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial that will test the effects of intermittent fasting (IF)&#xD;
      in subjects with relapsing-remitting MS (RRMS). The goal of this clinical trial is to acquire&#xD;
      objective evidence regarding whether an IF diet has beneficial effects in MS patients.Two&#xD;
      dietary regimens, IF and western diet, will be compared in a randomized, controlled,&#xD;
      single-blinded 12 week trial in RRMS patients. This is a single-center study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RRMS patients will be enrolled in a randomized, controlled, single-blinded 12 week trial in&#xD;
      which IF will be compared to a standard western diet. Patients will be recruited at the John&#xD;
      L. Trotter MS center and randomly assigned to either a standard western diet or an IF diet&#xD;
      (1:1). Enrolled subjects will complete a clinical and laboratory assessment before starting&#xD;
      the diet (baseline), at week 6 and at end of the study (week 12). The primary outcome will be&#xD;
      leptin at week 12 measured in the peripheral blood. Secondary outcomes will be: 1) peripheral&#xD;
      blood metabolic profiling; 2) anthropometric (body mass index and waist circumference) and&#xD;
      total body fat measures; 3) gut microbiota richness and composition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcome assessors will be blinded to the intervention because they will not know the group assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Leptin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Leptin at week 12 measured in the peripheral blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peripheral metabolic and inflammatory profiling</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adipokine and inflammatory markers at week 12 measured in the peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric measure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Weight and height will be combined to report BMI in kg/mg^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric measure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Waist circumference in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota</measure>
    <time_frame>12 weeks</time_frame>
    <description>Gut microbiota richness and composition</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Intermittent fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects randomized to this group will do IF by restricting their diet and consuming few calories two days per week. During the days of fasting, subjects will be allowed to drink water, calorie-free beverages, and eat fresh, steamed or roasted non-starchy vegetables.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Western diet</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The subjects randomized to this group will eat a standard western style diet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intermittent fasting</intervention_name>
    <description>the subjects randomized to this group will do IF by restricting their diet and consuming few calories two days per week. During the days of fasting, subjects will be allowed to drink water, calorie-free beverages, and eat fresh, steamed or roasted non-starchy vegetables.</description>
    <arm_group_label>Intermittent fasting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of RRMS (2010 Mc Donald criteria).&#xD;
&#xD;
          -  EDSS &lt;6.0 and disease duration ≤ 15 years.&#xD;
&#xD;
          -  On an injectable therapy for MS, glatiramer acetate (GA) or beta-interferon (beta-IFN)&#xD;
             for at least 3 months prior to the study and with no anticipated changes of the&#xD;
             medication for the 12 week study duration.&#xD;
&#xD;
          -  Age ≥18 years.&#xD;
&#xD;
          -  BMI &gt; 22 and &lt; 35 kg/m2 with stable weight in the 3 months prior to screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any chronic disease process (excluding MS) that could interfere with&#xD;
             interpretation of results.&#xD;
&#xD;
          -  Diagnosis in the past of an eating disorder (anorexia, bulimia, or binge eating).&#xD;
&#xD;
          -  Relapsing at the time of enrollment.&#xD;
&#xD;
          -  On corticosteroid treatment (oral or intravenous) in the past month. Nasal&#xD;
             corticosteroid treatments are allowed.&#xD;
&#xD;
          -  Diagnosis of diabetes or at time of OGTT (fasting glucose &gt;126 mg/dl or &gt; 200 mg/dl at&#xD;
             2 hours with a load of 75 g of glucose&#xD;
&#xD;
          -  History of food allergies or food intolerance that would interfere with the study.&#xD;
&#xD;
          -  History of antibiotic treatment within the past 3 months prior to enrollment&#xD;
&#xD;
          -  Use of anticoagulant drugs (like Warfarin or Coumadin) that need to monitor their&#xD;
             intake of vegetables containing high levels of vitamin K.&#xD;
&#xD;
          -  Currently on a special diet and not willing to stop at least one month prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Currently taking omega 3/fish oil supplements and not willing to stop administration&#xD;
             one month prior to enrollment&#xD;
&#xD;
          -  Currently pregnant or plan to become pregnant within 6 months&#xD;
&#xD;
          -  Current tobacco or e-cigarette smoker&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laura Piccio, MD, PhD</last_name>
    <phone>3147474591</phone>
    <email>picciol@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valeria Tosti, MD</last_name>
    <phone>314-362-2394</phone>
    <email>vtosti@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University in St Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Piccio, MD, PhD</last_name>
      <phone>314-747-4591</phone>
      <email>picciol@neuro.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Valeria Tosti, MD</last_name>
      <phone>314-362-2394</phone>
      <email>vtosti@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Laura Piccio, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 27, 2018</study_first_submitted>
  <study_first_submitted_qc>May 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2018</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Intermittent fasting</keyword>
  <keyword>western diet</keyword>
  <keyword>microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

